Our partners, page-10

First 10 Last

Share
Profile

Follow
slippin

8,208 Posts.

1138

13/03/20

00:01

Post #: 43462216
Share

Originally posted by Stockcount ↑

say what ?

why wouldn't they be able to tell us ? they are telling the whole world they are putting together a test.

You think they aren't going to confirm a partner because then the competition knows how the test is going to work ? I don't think so.

We are not in the test. period.

There is nothing being said by anyone and no rumours or whiffs on the grapevine. No extra buying. Nada.

Surges, you said the coronavirus panic would last a few days. Clearly wrong. A month already and still getting worse ! Down another 7.5 % today !
And the USA is about to feel the full intensity of the impact. If cases and deaths mount up like in china, and the US or A starts shutting down the largest economy in the world, its going to get pretty bad before it gets better.

A market analyst that personally and frankly sounded on the money, said this is probably going to be the frenzy week. It's going to be volatile from here for a few more weeks but stay within this sort of range. Then slowly return to some sort of normal over coming months.

I'm no market analyst but think its going to be a frenzy month not a week and its affects will linger for months not weeks.

Trump banned travel from Europe to the USA today ... WTF is that !

Expand

I think the financial effects will last for years, not months. However, batteries and battery improvements are not going away. As well as that, fast accurate point of care testing will grow exponentially. Not just for this virus, but the world is learning a harsh lesson.

ADO Price at posting: 1.6¢ Sentiment: Buy Disclosure: Held
14 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 927 more messages in this thread...

First 10 Last

Add ADO (ASX) to my watchlist

(20min delay)
Last 2.2¢		Change 0.001(4.76%)		Mkt cap ! $54.77M

Open	High	Low	Value	Volume
2.1¢	2.2¢	2.1¢	$21.58K	1.020M

Buyers (Bids)

No.	Vol.	Price($)
1	100000	2.1¢

Sellers (Offers)

Price($)	Vol.	No.
2.2¢	378168	5

View Market Depth

No.	Vol.	Price($)
1	100000	0.021
10	1443457	0.020
10	2127381	0.019
5	1657002	0.018
4	1574748	0.017

Price($)	Vol.	No.
0.022	378168	5
0.023	642868	9
0.024	141966	2
0.025	478846	7
0.026	83915	2

Last trade - 16.10pm 07/10/2024 (20 minute delay)

ADO (ASX) Chart

Our partners, page-10

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Our partners, page-10

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News